Differential Impact of a Multicomponent Goals-of-Care Program in Patients with Hematologic and Solid Malignancies

Author:

Hui David1ORCID,Ahmed Sairah23ORCID,Nortje Nico4ORCID,George Marina5,Andersen Clark R.6ORCID,Wilson Kaycee7,Urbauer Diana6ORCID,Flowers Christopher28,Bruera Eduardo1

Affiliation:

1. Department of Palliative, Rehabilitation and Integrative Medicine, MD Anderson Cancer Center, Houston, TX 77030, USA

2. Department of Lymphoma and Myeloma, MD Anderson Cancer Center, Houston, TX 77030, USA

3. Department of Stem Cell Transplant and Cellular Therapy, MD Anderson Cancer Center, Houston, TX 77030, USA

4. Department of Critical Care Medicine, MD Anderson Cancer Center, Houston, TX 77030, USA

5. Department of Hospital Medicine, Division of Internal Medicine, Houston, TX 77030, USA

6. Department of Biostatistics, MD Anderson Cancer Center, Houston, TX 77030, USA

7. Department of Inpatient Analytics, MD Anderson Cancer Center, Houston, TX 77030, USA

8. Division of Cancer Medicine, MD Anderson Cancer Center, Houston, TX 77030, USA

Abstract

We recently reported that an interdisciplinary multicomponent goals-of-care (myGOC) program was associated with an improvement in goals-of-care (GOC) documentation and hospital outcomes; however, it is unclear if the benefit was uniform between patients with hematologic malignancies and solid tumors. In this retrospective cohort study, we compared the change in hospital outcomes and GOC documentation before and after myGOC program implementation between patients with hematologic malignancies and solid tumors. We examined the change in outcomes in consecutive medical inpatients before (May 2019–December 2019) and after (May 2020–December 2020) implementation of the myGOC program. The primary outcome was intensive care unit (ICU) mortality. Secondary outcomes included GOC documentation. In total, 5036 (43.4%) patients with hematologic malignancies and 6563 (56.6%) with solid tumors were included. Patients with hematologic malignancies had no significant change in ICU mortality between 2019 and 2020 (26.4% vs. 28.3%), while patients with solid tumors had a significant reduction (32.6% vs. 18.8%) with a significant between-group difference (OR 2.29, 95% CI 1.35, 3.88; p = 0.004). GOC documentation improved significantly in both groups, with greater changes observed in the hematologic group. Despite greater GOC documentation in the hematologic group, ICU mortality only improved in patients with solid tumors.

Funder

National Cancer Institute

MD Anderson’s Cancer Center Support

Publisher

MDPI AG

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3